NEW YORK (GenomeWeb News) – BG Medicine today reported second quarter revenues of $799,000, down 20 percent from $1.0 million in the second quarter of 2013.

The revenues consisted solely of product revenues from sales of the company's BGM Galectin-3 test. Product revenues were down 18 percent from $972,000 in Q2 2013.

The company reported no service revenues. It reported $34,000 in service revenues in the year-ago period.

BG also lowered its full-year 2014 guidance, noting that it no longer expects 2014 revenues to exceed 2013 revenues.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.

Jun
19
Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.